Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism
Objective: We set out to compare patterns of dyskinetic behaviours induced by the systemic administration of L-DOPA and D1 or D2 receptor (D1R, D2R) agonists…Analysis of handgrip strength, upper limb traction and ground reaction force on bus step climb in healthy elderly subjects and individuals with Parkinson’s disease
Objective: To analyze and compare the strength hand, upper limbs traction strength and the ground reaction force (FRS) during step up in a bus, in…Efficacy of opicapone according to levodopa’s duration of use in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation (MF) according to levodopa’s duration of use. Background: OPC…The ADOPTION (eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs) study in Parkinson’s disease: design and rationale of a randomized prospective, open-label exploratory trial
Objective: This study aims to explore the potential of opicapone (OPC) to optimize levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) as first-line approach to treat wearing-off in…OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations
Objective: To conduct a longitudinal real-world study that examines treatment patterns, clinical outcomes, safety and tolerability of opicapone as an adjunctive treatment to carbidopa/levodopa (CD/LD)…Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS
Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study
Objective: This study aimed to explore patients’ adherence to antiparkinsonian medication, and to determine factors associated with low adherence among Serbian PD patients. Background: Adherence…Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease
Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…
- « Previous Page
- 1
- …
- 397
- 398
- 399
- 400
- 401
- …
- 436
- Next Page »